Skip to main content

Advertisement

Table 1 Pain and functional outcomes before and after anterior cruciate ligament transection in dogs

From: Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model

  Time  
Evaluation methods/Groups Baseline Week 4 Week 8 P-values
Function - kinetic gait analysis (%BW)     
Placebo-control 71.4 (3.7) 27 (11.0) 32.2 (12.4) *<0.01
Tiludronate 73.6 (6.1) 35.1 (15.5) 43.6 (9.0) § = 0.05 ¶ <0.01
Pain - Visual analog scale (VAS, measurement)     
Placebo-control 0.0 (0.0) 37.6 (14.3) 26.8 (11.1) *<0.01
Tiludronate 0.0 (0.0) 26.9 (18.9) 15.6 (9.2)  
Pain - Numerical rating scale (NRS, score)     
Placebo-control 0.0 (0.0) 19.4 (4.3) 18.3 (3.7)  
Tiludronate 0.0 (0.0) 15.5 (5.4) 15.0 (3.4) § = 0.03
Pain - Electrodermal activity (EDA, reading)     
Placebo-control 4.5 (2.5) 6.4 (2.5) 5.3 (2.4)  
Tiludronate 4.2 (2.7) 3.6 (2.5) 3.9 (2.4)  
Function - Telemetered actimetry recording (count)     
Daily averaged total intensity (DATI, no unit)     
Placebo-control 97.9 (41.4) 79.1 (22.7) 85.7 (35.8)  
Tiludronate 82.3 (25.4) 104.5 (44.6) 91.2 (33.1) ¶ = 0.04
Daily averaged active intensity (DAAI, no unit)     
Placebo-control 390.9 (101.3) 360.6 (73.9) 379.1 (127.1)  
Tiludronate 390.2 (82.9) 502.6 (145.7) 443.1 (117.1) ¶ = 0.04
  1. Tiludronate was injected subcutaneously at 2 mg/kg, starting immediately on the day of ACL transection and repeated every two weeks for an eight-week follow-up. Placebo-control dogs received mannitol injection in a similar fashion.
  2. Data presented are mean (SD).
  3. Statistically significant Time effect (*), Group effect (§) and Time per Group interaction (¶)